Two Biopharmaceutical Organizations Award More Than $1.4 Million in Studies to eResearchTechnology for Cardiac Safety Monitoring

Two Biopharmaceutical Organizations Award More Than $1.4 Million
in Studies to eResearchTechnology for Cardiac Safety Monitoring and Information
Distribution Services
Two Thorough Phase I ECG Studies Include New Study Design and Baseline Study
Capable of Extension 


PHILADELPHIA, March 31  /PRNewswire-FirstCall/ -- eResearchTechnology, Inc.
(eRT) , a leading provider of centralized electrocardiographic (ECG) collection
and interpretation services, announced today that it has received agreements for
more than $1.4 million in cardiac safety monitoring and services from a top 50
pharmaceutical and growing biotechnology organization for two drug candidates in
clinical development.

The agreements cover two extensive Phase I studies for which eRT is providing
comprehensive support including the provision, training and ongoing assistance
required for effective use of digital 12-lead Holter equipment designed to
facilitate 24-hour digital recording of cardiac safety data that is subsequently
provided to eRT for analysis.  eRT will perform digital collection, measurement,
interpretation, review, and distribution of cardiac safety data through its
EXPeRT workflow enabled data handling technology, the first solution in
production thatwas designed explicitly to meet emerging international
regulatory guidance and technical standards.  The studies are targeted for
completion over a 90-day period.

"We are excited by eRT having been selected to provide comprehensive cardiac
safety services for these Thorough Phase I ECG studies, each of which provides a
unique opportunity to marry eRT's capabilities with sponsor requirements," said
Scott Grisanti, senior vice president of business development and chief
marketing officer at eRT.  "Thefirst study, which is a pilot being conducted on
behalf of a global top 50 pharmaceutical organization, is advancing a key aspect
of study design that will provide more flexibility to the entire industry.  The
second study is being conducted for an emerging biotechnology organization,
which is leveraging eRT's digital Holter platform to provide the flexibility to
add 12-lead ECG time points for analysis at any time during or after conduct of
the study with determination of an optimal ECG collection profile."

Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com/) is a
provider of technology and services to the pharmaceutical, biotechnology and
medical device industries on a global basis.  The company is a market leader in
providing centralized core-diagnostic electrocardiographic (ECG) technology and
services to evaluate cardiac safety in clinical development.  The company is
also a leader in providing technology and services to streamline the clinical
trials process by enabling its customers to automate the collection, analysis,
and distribution of clinical data in all phases of clinical development.

Statements included in this release may constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995. 
Such statements involve a number of risks and uncertainties such as competitive
factors, technological development, market demand, and the company's ability to
obtain new contracts and accurately estimate net revenues due to variability in
size, scope and duration of projects, and internal issues in the sponsoring
client.  The sponsors may cancel these agreements at their sole discretion.  As
a result, actual results may differ materially from any financial outlooks
stated herein.  Further information on potential factors that could affect the
company's financial results can be found in the company's Reports on Forms 10-K
and 10-Q filed with the Securities and Exchange Commission. 

DATASOURCE: eResearchTechnology, Inc.



CONTACT:  Joan Sterlacci, eResearchTechnology, Inc., [phone]; or

Matt Hayden, Hayden Communications, [phone], for eResearchTechnology



Web site:  http://www.ert.com/ 

Copyright